Vical Reports Third Quarter 2016 Financial Results

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three and nine months ended September 30, 2016. Net loss for the third quarter of 2016 was $2.5 million, or $0.24 per share, compared with a net loss of $0.3 million, or $0.03 per share, for the third quarter of 2015. Revenues for the third quarter of 2016 were $2.6 million, compared with revenues of $5.0 million for the third quarter of 2015, reflecting revenues from Astellas Pharma Inc. for manufacturing services performed under the ASP0113 collaborative agreements. ASP0113 is Vical’s therapeutic vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in transplant recipients.

Vical had cash and investments of $43.0 million at September 30, 2016. The Company’s net cash use for the first nine months of 2016 was $6.8 million, which was consistent with the Company’s guidance for the full year. The Company is projecting net cash burn for 2016 between $8 million and $11 million.

Operational updates include:

ASP0113 CMV Vaccine

  • Recruitment in the multinational Phase 3 registration trial in hematopoietic cell transplant (HCT) recipients met its target enrollment of 500 subjects in September and is now fully enrolled. The primary endpoint of the trial is a composite of overall mortality and CMV end organ disease which will be assessed one year after transplantation. Astellas now expects top-line data to be available in the first quarter of 2018. Vical and Astellas continue to make substantial progress in process validation activities for the manufacture of the bulk drug product in anticipation of a potential BLA filing in 2018.

HSV-2 Therapeutic Vaccine

  • In September 2016, Vical announced the initiation of a Phase 2 trial of its bivalent HSV-2 therapeutic vaccine. The randomized, double-blind, placebo-controlled trial is being conducted at approximately 15 U.S. clinical sites and will evaluate the efficacy and safety of the vaccine in approximately 225 otherwise healthy adults aged 18 to 50 years with symptomatic genital HSV-2 infection. The primary endpoint of the study is annualized lesion recurrence rate and was selected following consultation with clinical experts and the FDA. This endpoint is clinically meaningful for both patients and treating physicians as it provides important information on both the number and spacing of recurrences over time in this chronic disease setting.

VL-2397 Antifungal

  • Dosing has been completed in Vical’s first-in-human Phase 1 trial of its novel antifungal, VL-2397. The randomized, double-blind, placebo-controlled trial is designed to evaluate safety, tolerability and pharmacokinetics of single and multiple ascending doses of intravenous VL-2397 in healthy volunteers. Safety follow-ups and pharmacokinetic sampling are expected to be completed by the end of 2016 with data to follow in 2017. Vical is working actively with its expert advisors and the FDA to design a Phase 2 efficacy study to evaluate VL-2397 in the treatment of patients with invasive aspergillosis. This fungal infection represents a sizeable unmet need given the high mortality rate in immunocompromised patients, despite available antifungal therapies.

Vical will conduct a conference call and webcast today, November 3, at noon Eastern Time, to discuss the Company’s financial results and program updates with invited participants. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (785)830-7992 (preferred), or (800)768-6569 (toll-free), and reference confirmation code 1380572. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 1380572. The call will also be available live and archived through the events page at For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by e-mail at

About Vical

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include net cash use guidance, as well as anticipated developments in independent and collaborative programs, including the plans, timing of initiation, enrollment and announcement of data for clinical trials, plans and timing of regulatory filings and potential markets for Vical’s product candidates. Risks and uncertainties include whether Vical or others will continue development of ASP0113, Vical’s HSV-2 vaccine, VL-2397 or any other independent or collaborative programs; whether Vical will achieve levels of revenues and control expenses to meet its financial projections; whether enrollment in on-going trials will continue at current rates; whether Vical or its collaboration partners will be able to obtain regulatory allowances or guidance necessary to proceed with proposed clinical trials or implement anticipated clinical trial designs; whether on-going or planned clinical trials will be initiated or completed on the timelines Vical currently expects; whether any product candidates will be shown to be safe and efficacious in clinical trials; whether Vical is able to continue its collaborative arrangements or enter into new ones; whether Vical will have access to sufficient capital to fund its planned development activities; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

Selected Condensed Financial Information (Unaudited) 
 Three Months Ended Nine Months Ended 
Statements of OperationsSeptember 30, September 30, 
(in thousands, except per share amounts)2016 2015 2016 2015 
  Contract revenue $    2,310   $    4,427   $    10,028   $    12,382  
  License and royalty revenue    332      590      1,340      1,755  
Total revenues    2,642      5,017      11,368      14,137  
Operating expenses:            
  Research and development    2,599      2,128      7,380      8,222  
  Manufacturing and production    993      1,306      5,060      6,626  
  General and administrative    1,621      1,916      5,330      6,271  
Total operating expenses    5,213      5,350      17,770      21,119  
  Loss from operations    (2,571)     (333)     (6,402)     (6,982) 
  Net investment and other income    48      33      201      99  
Net loss $    (2,523)  $    (300)  $    (6,201)  $    (6,883) 
Basic and diluted net loss per share $    (0.24)  $    (0.03)  $    (0.64)  $    (0.75) 
Weighted average shares used in computing            
  basic and diluted net loss per share  10,453   9,196   9,647   9,160 
Balance Sheets      September 30, December 31, 
(in thousands)      2016 2015 
  Cash, cash equivalents, and marketable            
   securities, including restricted       $    40,761   $    39,954  
  Other current assets          6,249      4,544  
Total current assets          47,010      44,498  
Long-term investments          2,217      2,052  
Property and equipment, net          1,375      1,873  
Other assets          1,226      1,491  
Total assets       $    51,828   $    49,914  
Liabilities and stockholders' equity:            
  Current liabilities       $    3,965   $    4,162  
  Long-term liabilities          -      359  
  Stockholders' equity          47,863      45,393  
Total liabilities and stockholders' equity       $    51,828   $    49,914  



Contact Data